Home › Trial NCT06928376
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
- Trial IDNCT06928376
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorChinese PLA General Hospital
- Enrollment160
- Start date2024-04-18
- ConditionsAcute Myeloid Leukemia · First Line Therapy
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.